000			01569nam a2200133Ia 4500
008			220616s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aNew Therapies of Liver Diseases
546			_aEnglish[eng]
650			_atolvaptan||cirrhotic ascites||survival rate||furosemide||primary biliary cholangitis||autoantibodies||ursodeoxycholic acid||treatment response||second line therapy||primary biliary cholangitis (PBC)||primary sclerosing cholangitis (PSC)||clinical trials||ursodeoxycholic acid (UDCA)||Farnesoid X Receptor (FXR) agonist||Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists||liver cancer||systemic treatment||immunotherapy||real-world||unresectable hepatocellular carcinoma||cirrhosis||decompensation||bleeding||varices||survival||infection||alcoholic hepatitis||acute-on-chronic liver failure||cholangiocarcinoma||colorectal cancer metastases||hepatocellular carcinoma||liver transplantation||Milan criteria||alpha-fetoprotein||solid organ transplantation||liver injury||immunosuppressant||SARS-CoV-2||humoral response||vaccination||portal-systemic shunt||ammonia||vigilance||HBV||HDV||antivirals||functional cure||pharmacology||acute-on-chronic liver failure (ACLF)||liver transplantation (LT)||decompensated cirrhosis||portal hypertension||ascites||non-selective beta-blockers||TIPS||rifaximin||human albumin||statins||targeted therapy||effective hypovolemia||anti-mineralocorticoids||loop diuretics||vaptans||n/a
700			_aToniutto, Pierluigi
856			_uhttps://mdpi.com/books/pdfview/book/5398
942			_cEB
999			_c20498 _d20498